ΔΗΜΟΣΙΕΥΜΕΝΑ ΑΡΘΡΑ ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ

1. Chemioterapia 6: 393-395 (1987)

Combination chemotherapy with prednimustine, adriamycin, vincristine (VAP) in
advanced breast cancer. A phase II study.

Kosmidis PA, Fountzilas G, Athanassiou A, Karabelis A, Mylonakis N, Tsavaris N,
Karvounis N, Bacojiannis C

2. Oncology, 47, 70-4, 1990

Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil.

Tsavaris N, Karagiaouris P, Vonorta K, Bacogianis H, Milonakis N, Karvounis N, Kakoliris S, Zepou E, Karabelis A, Papazahariou M, et al

3. Eur J Cancer, 26 : 1054-6, (1990)

Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma

Tsavaris N, Bacoyannis C, Milonakis N, Sarafidou M, Zamanis N, Magoulas D, Kosmidis P

4. J Dermatol Surg Oncol 16: 519-522 (1990)

Conservative approach to the treatment of chemotherapy-induced extravasation.

Tsavaris NB, Karagiaouris P, Tzannou I, Komitsopoulou P, Bacoyiannis C,
Karabellis A, Papanicolaou V, Mylonakis N, Karvounis N, Zoannou A, Kosmidis P.

5. Acta Oncol 29: 1005-1009 , 1990

Comparison of antiemetic activity of chloropromazine and high doses of
metoclopramide in cisplatin-based chemotherapy.

Tsavaris NB, Papaioannou D, Beldecos D, Kakoliris S, Mylonakis N, Karvounis N,
Komitsopoulou P, Karagiaouris P, Sarmas J, Tzannou I, et al

6. J.Exp.Clin.Cancer 9:214-219, 1990
Alternative administration of Epirubicin, Vincristine and Mitoxantron , Vincristine in advanced Breast cancer
Kosmidis P, Fountzilas G, Tsavaris N, Kalogera-fountzila A, Karabelis A, Bacoyiannis C, Karvounis N, Mylonakis N.

7. Journal of Internal Medicine 228: 451-455, 1990
A randomized trial of the effect of three non steroid anti-inflamatory agents in ameliorating cancer-induced fever
Tsavaris N, Zinelis A, Karabelis A, Beldecos D, Bacoyiannis C, Milonacis N, Karvounis N, Kosmidis P

8. Journal of .Chemotherapy 2:123-126, 1990.
Multimodal biochemical modulation of 5-Fluorouracil activity in advanced colorectal cancer with Allopurinol, Follinic Acid and Dipyridamol.
Tsavaris N, Zinelis A, Karvounis N, Beldecos D, Mylonakis N, Zamanis N, Bacoyiannis C, Valilis P, Antonopoulos A, Kosmidis P.

9. J.Exp.Clin.Cancer Res 9: 151-154, 1990.
Exacerbation of disease by using LH-RH analog (Buserelin) in advanced Breast cancer.
Kosmidis P, Vonorta K, Tsavaris N, Karabelis A, Karvounis N, Mylonakis N.

10. J Pain Symptom Manage 6: 461-465 (1991)

Diphenhydramine for nausea and vomiting related to cancer chemotherapy with
cisplatin.

Tsavaris N, Zamanis N, Zinelis A, Tsoutsos E, Mylonakis N, Bacoyannis C,
Valilis P, Sarafidou M, Kosmidis P

11. J. Clin. Oncol. 10: 1153-1157 (1992)

The prognostic significance of immune changes in patients with renal cell
carcinoma treated with interferon alfa-2b.

Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E,
Bacoyiannis C, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A, et al

12. Ann. Oncol. 3: 127-130 (1992)

A randomized prospective study of cisplatin and vinblastine versus cisplatin,
vinblastine and mitomycin in advanced non-small cell lung cancer.

Mylonakis N, Tsavaris N, Bacoyiannis C, Karvounis N, Kakolyris S, Karabelis A,
Beer M, Kosmidis P

13. Cancer Chemother Pharmacol 30: 330-333 (1992)

Prevention of tissue necrosis due to accidental extravasation of cytostatic
drugs by a conservative approach.

Tsavaris NB, Komitsopoulou P, Karagiaouris P, Loukatou P, Tzannou I, Mylonakis
N, Kosmidis P

14. Oncology 49: 479-483 (1992)

Antiemetic efficacy of high-dose metoclopramide and dexamethasone in patients
receiving cisplatin chemotherapy: a randomized trial.

Tsavaris N, Tsaroucha-Noutsou E, Bacoyannis C, Mylonakis N, Valilis P,
Kozatsani-Halividi D, Tsoutsos H, Droufakou S, Kosmidis P

15.Eur J Cancer 29A, , 851-3, 1993

First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer.

Bafaloukos D, Samonis G, Klinaki A , Daliani D, Karvounis N, Bacoyiannis C, Karabelis A,
Milonakis N, Kosmidis P

16. Chemotherapy 39: 361-366 (1993)

Treatment of renal cell carcinoma with escalating doses of alpha-interferon.

Tsavaris N, Mylonakis N, Bacoyiannis C, Tsoutsos H, Karabelis A, Kosmidis P

17. Int J Biol Markers 8: 88-93 (1993)

Carcinoembryonic antigen (CEA), alpha-fetoprotein, CA 19.9 and CA 125 in
advanced colorectal cancer (ACC).

Tsavaris N, Vonorta K, Tsoutsos H, Kozatsani-Halividi D, Mylonakis N,
Papagrigoriou D, Koutsiouba-Kazakou P, Kosmidis P

18. Ann. Oncol. 5: 601-607 (1994)

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and
irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group
study.

Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P,
Mylonakis N, Provata A, Papadakis E, Klouvas G, et al

19. Lung Cancer 11: 299-303 (1994)

Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma

Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D,
Pavlidis N, Stamatelos G, Kosmidis P

20. Annals of Oncology 5: 159-162 (1994)

A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin
and vinblastine in non-operable non-small-cell lung cancer. A study of the
Hellenic Co-operative Oncology Group for Lung Cancer Trials.

Kosmidis P, Mylonakis N, Skarlos DV, Samantas E, Beer M, Theocharis D,
Zachariadis E, Gioti A, Papadakis E, Poulakis N, et al

21. J.Exp.Clin.Caner Res 13,4 405-408 1994
An Alternative Schedule Based on Ifosfamide (IFM) in Combination with Doxorubicin (ADM), Vincristin (VCR) and Actinomycin D (ACTD) in Advanced Soft Tissue Sarcomas (STS) of Adults. A Pilot Study.
Tsavaris N, Bacoyiannis C, Mylonakis N, Karvounis N, Zinelis A, Tsoutsos E, Kosmidis P.

22. Journal of Pain and Symptom Management 9 :254-258, 1994
Comparison of Ondansentron versus Ondansentron Plus Methylprednisolone as Antiemetic prophylaxis During Cisplatin-Containing Chemotherapy.
Nicolas Tsavaris, Nicolas Mylonakis, Charalampos Bacoyiannis, Michalis Katsikas, Athina Lioni, and Paris Kosmidis.

23. Oncology 52: 315-318 (1995)

Efficacy of ondansetron treatment with different timing schedules: a randomized
double-blind study.

Tsavaris N, Mylonakis N, Bacoyiannis C, Karvounis N, Charalambidis G, Pagou M,
Lioni A, Daliani D, Kosmidis P

24. J Chemother 7: 71-77 (1995)

A comparative study with two administration schedules of leucovorin and
5-fluorouracil in advanced colorectal cancer.

Tsavaris N, Foutzilas G, Markantonakis P, Mylonakis N, Bacoyannis C, Zisiadis
A, Basdanis G, Karvounis N, Sobolos K, Kosmidis P

25. Acta Oncol 34: 243-246 (1995)

Ondansetron versus metoclopramide as antiemetic treatment during
cisplatin-based chemotherapy. A prospective study with special regard to regard
to electrolyte imbalance.

Tsavaris N, Charalambidis G, Ganas N, Pagou M, Karabellis A, Mylonakis N, Benou
N, Tsikalakis D, Kosmidis P

26. Seminars in Oncology, vol 23, No 6, Suppl 15 (December), 1996: pp16-18

Paclitaxel and Carboplatin in Nonoperable Non-Small Cell Lung Cancer

Kosmidis P, Mylonakis N, Fountzilas G, Samantas E, Athanasiadis A, Skarlos D.

27. Chemotherapy 42: 220-226 (1996)

A Randomized Trial Comparing Adjuvant Fluorouracil, Epirubicin, and Mitomycin with No Treatment in Operable gastric Cancer

Tsavaris N, Tentas K, Kosmidis P, Mylonakis N, Sakelaropoulos N, Kosmas Ch, Lisaios B, Soumilas A, Mandrekas D, Tsetis A, Klonaris Ch.

28. Am J Clin Oncol 19: 517-521 (1996)

5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin,
mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.

Tsavaris NB, Tentas K, Kosmidis P, Mylonakis N, Sakelaropoulos N, Kosmas C,
Lisaios B, Soumilas A, Mandrekois D, Tsetis A, Klonaris C

29. Ann. Oncol. 7: 517-520 (1996)

A prospective randomized phase III study in non-small-cell lung cancer
comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide
and etoposide (VIP-16)

Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A,
Kattis K, Skarlos D

30. Eur. J. Cancer 32A: 421-428 (1996)

Carboplatin alone compared with its combination with epirubicin and
cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic
co-operative oncology group study.

Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M,
Mylonakis N, Makrantonakis P, Klouvas G, Karpathios S, Linardou H, Konstantaras
C, Fountzilas G

31. Oncology 53: 137-146 (1996)

Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as
adjuvant treatment in node-positive breast cancer patients. A Hellenic
Cooperative Oncology Group Study.

Fountzilas G, Polichronis A, Katsohis K, Gennatas K, Toussis D, Skarlos D,
Kosmidis P, Vassilaros S, Semoglou C, Giannakakis T, Fahantidis E, Klouvas G,
Tsavaris N, Konstantaras C, Makrantonakis P, Kolotas C, Zamboglou N, Tsiliakos
S, Hainoglou D, Mylonakis N, Pavlidis N

32.Annals of Oncology, 8(7):697-699 (1997)

Paclitaxel and Carboplatin in inoperable non-small-cell lung cancer. A phase II study

Kosmidis P.A, Mylonakis N, Fountzilas G, Samantas E, Athanassiadis A, Andreopoulou E, Pavlidis N, Skarlos D.

33.Seminars in Oncology, 24(4Supl12):S12-30-S12-33 (1997)

Paclitaxel(175/m2) plus Carboplatin Versus Paclitaxel(225mg/m2) plus Carboplatin in Non-Small Cell Lung Cancer.A randomized Study

Kosmidis P, Mylonakis N, Fountzilas G, Samantas E, Athanassiadis A, Pavlidis N, Skarlos D.

34.Anticancer Research, 17(5/B):3799-3802 (1997)

Combination chemotherapy with Cisplatin and/or Doxorubicin in Malignant Mesothelioma. A Prospective study.

Tsavaris N, Primikirios N, Mylonakis N, Varouchakis G, Dosios T, Pavlidis N, Skarlos D, Tasopoulos T, Dritsas J, Kosmidis P.

35. International Journal of Oncology, 5(5):1147-1156 (1998)

Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy

Tsavaris N, Mylonakis N, Bacoyiannis C, Kosmas C, Kalergis G, Iakovidis V, Tzaninis , Kosmidis P.

36.Oncology, 55(6):513-516 (1998)

A Randomized Comparative Study of Antiemetic Prophylaxis with Ondansentron in a single 32 mg Loading dose versus 8mg every 6h in Patients Undergoing Cisplatin-based Chemotherapy.

Tsavaris N, Mylonakis N, Cosmas Ch, Bacoyiannis Ch.

37. Lung Cancer , 23: 159-168 (1999)

Combination Chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell Lung Cancer.

Samantas E, Skarlos DV, Pectasidis D, Nicolaides P, kalofonos H, Mylonakis N et al

38. Seminars in Oncology, Supp/18(6):25 (1999)

A multicenter Randomized Phase III study of Paclitaxel (175mg/m2) plus Carboplatin (AUC 6) Versus Paclitaxel (225mg/m2) plus Carboplatin (AUC ^) in Advanced Non-Small Cell Lung Cancer (NSCLC).

Skarlos DV, Mylonakis N, Fountzilas G, Samantas E, Dimopoulos M.A, Papadimitriou C, Kalofonos C, Pavlidis N, Papakonstantinou C, Kosmidis P.

39. Anticancer Res. 2000 Nov-Dec;20(6C):4777-83.

Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.

Tsavaris N, Kosmas C, Mylonakis N, Bacoyiannis C, Kalergis G, Vadiaka M, Boulamatsis D, Iakovidis V, Kosmidis P. Related Articles, Links

40. Seninars in Oncology 27(1suppl):3-8 (2000)

Combination Chemotherapy with Paclitaxel plus Carboplatin versus Paclitaxel plus Gemcitabine in inoperable non-small cell Lung Cancer.

Kosmidis P, Mylonakis N, Dimopoulos A et al

41.Ann Oncol 11 :1395-1397, 2000

Phase II study of Pegylated Liposomal Doxorubicin:is inactive in recurrent small cell lung cancer

Samantas E, Kalofonos H, Linardou H, Nicolaides C, Mylonakis N, Fountzilas G, Kosmidis P, Skarlos D.

42. Ann Oncol 11:799-805, 2000

Paclitaxel(175mg/m2) plus Carboplatin 6 AUC versus Paclitaxel (225mg/m2) plus Carboplatin 6 AUC in advanced non-small-cell lung cancer

Kosmidis P, Mylonakis N et al

43. Journal of Balcan Union of Oncology, 5(2):241-244 (2000)

Ocular toxicity due to high dose interferon adjuvant therapy in a patient with malignant melanoma: case report and review of literature

Panagiotou I, Bafaloukos D, Karabelis A, Poulimenos L, Chatzispasou E, Mylonakis N

44. Annals of Oncology, 11(11):1395-1397 (2001)

Phase II stydy of pegylated liposomal doxorubicin: inactive in recurrent small-cell Lung Cancer. A Hellenic Cooperative Oncology Group Study

E.Samantas, H Kalofonos, H Linardou, C.Nicolaides, N Mylonakis, G Fountzilas, P Kosmidis, D Skarlos

45. Oncology. 2002;63(4):333-7

Docetaxel in combination with dacarbazine in patients with advanced melanoma.

.Bafaloukos D, Aravantinos G, Fountzilas G, Stathopoulos G, Gogas H, Samonis G, Briasoulis E, Mylonakis N, Skarlos DV, Kosmidis P.

46. Am J Clin Oncol Feb;25(1):23-30 (2002)

A Phase III study of 5-Fluorouracil plus Interferon alpha 2b versus 5-Fluorouracil plus Leucovorin in patients with advanced Colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study

Kalofonos HP, Nicolaides C, Samantas E, Mylonakis N, Aravantinos G, Dimopoulos MA, Gennatas C, Kouvatseas G, Giannoulis E, Dervenis C, Basdanis G, Pavlidis N, Androulakis I, Fountzilas G ; Hellenic Cooperative Oncology Group (HeCOG).

47. J Clin Oncol. 2002 Sep 1;20(17):3578-85.

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial

.Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M

48. Ann Oncol. 2003 Apr;14(4):537-42.
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study.
Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C.

49. Crit Rev Oncol Hematol. 2003 Mar;45(3):265-75.
An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer.
Kosmas C, Tsavaris N, Mylonakis N, Kalofonos HP

50.Pectasides D, Pectasides M, Farmakis D, Nikolaou M, Koumpou M, Kostopoulou V, Mylonakis N.

Testicular Function in Patients with Testicular Cancer Treated with Bleomycin-Etoposide-Carboplatin (BEC(90)) Combination Chemotherapy.
Eur Urol. 2004 Feb;45(2):187-93.
PMID: 14734005 [PubMed – in process] 51.Pectasides D, Mylonakis N, Farmakis D, Nikolaou M, Koumpou M, Katselis I, Gaglia A, Kostopoulou V, Karabelis A, Kosmas C.

Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
Anticancer Res. 2003 Sep-Oct;23(5b):4205-11.

52.Gemcitabine and Oxaliplatin(GEMOX) in patients with Cisplatin-refractory germ cell tumors: a pfase II study.
Pectasides D., Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D.
Ann Oncol 2004 Mar;15(3):493-7.

53. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third –line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D., Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Economopoulos T, Raptis SA.
Eur Urol. Aug;46(2):216-21.

54. Comparison of docetaxel and docetaxel-irinotecan combination as second –line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.
Pectasides D., Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, , Gaglia A, Koumpou M , Mylonakis N, Xiros N, Economopoulos T, Raptis SA.
Ann Oncol. 2005 Feb;16(2):294-9.

55. Intramedullary spinal cord metastases in breast cancer: report of four cases and review of literature.
Kosmas C, Koumpou M, Nikolaou M, Katselis J, Soukouli G, Markoutsaki N, Kostopoulou V, Gaglia A, Mylonakis N, Karabelis A, Pectasides D.
J Neurooncol. 2005 Jan;71(1):67-72. Review.

56.Changes of celebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Kosmas C, Tsavaris NB, Soukouli G, Gouveris P, Tsakonas G, Katselis J, Alexopoulos H, Mylonakis N, Karabelis A.
Med Oncol. 2005 ;22(2):123-8.

57. Celebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
Cosmas C, Tsavaris NB, Tsakonas G, Soukouli G, Gassiamis A, Mylonakis N, Karabelis A.
Med Sci Monit. 2005 Aug;11(8):CR398-401.

58. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
Kosamas C, Tsavaris N, Koutras A, Makatsonis T, Mylonakis N, Tzelepis G, Dimitrakopoulos A, Spyropoulos K, Polyzos A, Karabelis A, Kalofonos HP.
Oncology. 2005;69940;333-41.

59. Intramedullary spinal cord metastases from atypical small cell lung cancer: a case report and literature review.
Nikolaou M, Koumpou M, Mylonakis N, Karabelis A, Pectasides D, Kosmas C.
Cancer Invest. 2006 Feb24(1):46-9.

60. A phaserI-II study of bi-weekly gemcitabine and irinotecan as second line chemotherapy in non-small-cell lung cancer after prir taxane+platinum- based regimens.
Kosnas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsonis T, Mylonakis N, Karabelis N, Stathopoulos GP, Kalofonos HP.
Cancer Chemother Pharmacol. 2007 Jan;59(1):51-9.

61. Her-2/new status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D, Gaglia A, Arapantoni-Dadioti P, Valavanis C, Kostopoulou V, Mylonakis N, Pectasides M, Economopoulos T.
Anticancer Res. 2006 Jan-Feb;26(1B):647-53.

62. Rare and aggressive metastatic, axial multifocal local epithelioid sarcoma associated with paraneoplastic granulocytosis and hypoglycaemia.
Tsakonas GP, Kallistratos MS, Balamoti EK, Gassiamis A, ZIzi-Sermpetzoglou A, Mylonakis N, Karabelis A, Kosmas C.
Lancet Oncol. 2007 Jan;8(1):82-4.

63. Diffuse calcification of metastases after intensive multiagent chemotherapy in widespread osteosarkoma leading to death in a 18-year-old male: report of a case and literature review.
Gassiamis A, Tsakonas G, Soukouli G, Mylonakis N, Kosmas C.
Med Oncol. 2006;23(4):455-62.

64. Dose escalation of docetaxel and ifosfamide in patient with advanced breast cancer failing prior anthracyclines: mature results of a phase I-II study.
Cosmas C, Tsavaris N, Malamos N, Tsakonas G, Gassiamis A, Skopelitis H, Soukouli G, Polyzos A, Mylonakis N, Karabelis A.
J BUON 2005 jul-sep;10(3):337-46.

65. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
Cosmas C, Tsavaris N, Malamos N, Tsakonas G, Gassiamis A, Polyzos A, Mylonakis N, Karabelis A.
Invest New Drugs. 2007 Oct;25(5);463-70.

66. . Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.

Cosmas C, Tsavaris N, , Mylonakis N, Tsakonas G, Gassiamis A, Skopelitis H, Polyzos A, Malamos N Karabelis A.
J Chemother. 2007 June;19(3):322-31.

67. Cardiotoxicity of fluoropyrimidines in different schedulew of administration: a prospective study.
Cosmas CKallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N.
J Cancer Clin Oncol. 2008 Jan;134(1):75-82.

68. Multicenter phase-II trial of irinotecan plus oxalipplatin (IROX regimen) in patients with poor prognosis cancer of unknown primary: a Hellenic cooperative oncology group study.
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N.
Cancer Chemother Pharmacol. 2008 Jul;62(2):277-84.

69. Treatment strategies in CNS metastases.
Kosmas C, Tsakonas G, Mylonakis N.
Expert Opin Pharmacother. 2008 Aug;9(12):2087-98.